{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:10:57Z","timestamp":1782738657927,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.tranon.2020.100868","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T19:45:07Z","timestamp":1599767107000},"page":"100868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study"],"prefix":"10.1016","volume":"13","author":[{"given":"Xue-wen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-ru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ming","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-gao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-ping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-ying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2020.100868_bb0005","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jtcvs.2007.05.031","article-title":"Sarcomatoid lung cancer (spindle\/giant cells): an aggressive disease?","volume":"134","author":"Venissac","year":"2007","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"10.1016\/j.tranon.2020.100868_bb0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.surg.2012.05.007","article-title":"Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis","volume":"152","author":"Yendamuri","year":"2012","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.tranon.2020.100868_bb0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0748-7983(97)93733-1","article-title":"Biphasic sarcomatoid carcinoma of the lung: report of 5 cases and review of the literature","volume":"23","author":"Terzi","year":"1997","journal-title":"European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology"},{"issue":"9","key":"10.1016\/j.tranon.2020.100868_bb0020","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2007.05.006","article-title":"Palliative chemotherapy for pulmonary pleomorphic carcinoma","volume":"58","author":"Bae","year":"2007","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00408-015-9818-3","article-title":"Pulmonary carcinosarcoma arising in the framework of an idiopathic pulmonary fibrosis","volume":"194","author":"Lococo","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.tranon.2020.100868_bb0035","doi-asserted-by":"crossref","first-page":"167317","DOI":"10.1100\/2012\/167317","article-title":"Evaluation of six patients with pulmonary carcinosarcoma with a literature review","volume":"2012","author":"Sokucu","year":"2012","journal-title":"TheScientificWorldJournal"},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-1119(98)00264-9","article-title":"The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization","volume":"215","author":"Liu","year":"1998","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1359-6101(01)00029-6","article-title":"Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition","volume":"13","author":"Maulik","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"12","key":"10.1016\/j.tranon.2020.100868_bb0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.tranon.2020.100868_bb0055","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-Met signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"31","key":"10.1016\/j.tranon.2020.100868_bb0060","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.tranon.2020.100868_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JTO.0b013e318241655f","article-title":"c-MET\/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas","volume":"7","author":"Tsuta","year":"2012","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"52","key":"10.1016\/j.tranon.2020.100868_bb0070","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be MET?","volume":"12","author":"Drilon","year":"2017","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.bjc.6604781","article-title":"Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients","volume":"100","author":"Galleges Ruiz","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2020.100868_bb0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/JTO.0b013e3181d0a4db","article-title":"Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status","volume":"5","author":"Onitsuka","year":"2010","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2020.100868_bb0090","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)64096-5","article-title":"c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma","volume":"158","author":"Tokunou","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.tranon.2020.100868_bb0095","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol. Histopathol."},{"issue":"8","key":"10.1016\/j.tranon.2020.100868_bb0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.prp.2016.05.006","article-title":"Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: a meta-analysis","volume":"212","author":"Pyo","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.tranon.2020.100868_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"10","key":"10.1016\/j.tranon.2020.100868_bb0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2020.100868_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.tranon.2020.100868_bb0120","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","article-title":"Capmatinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.tranon.2020.100868_bb0125","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2016","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"26","key":"10.1016\/j.tranon.2020.100868_bb0130","doi-asserted-by":"crossref","first-page":"42428","DOI":"10.18632\/oncotarget.16403","article-title":"MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung","volume":"8","author":"Saffroy","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.tranon.2020.100868_bb0135","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2020.100868_bb0140","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.tranon.2020.100868_bb0145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.tranon.2020.100868_bb0150","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2020.100868_bb0155","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2018.08.008","article-title":"c-MET overexpression as a poor predictor of MET amplification or exon 14 mutation in lung sarcomatoid carcinoma","volume":"13","author":"Mignard","year":"2018","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2020.100868_bb0160","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"7","key":"10.1016\/j.tranon.2020.100868_bb0165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.tranon.2020.100868_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2017.02.008","article-title":"MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics","volume":"106","author":"Kwon","year":"2017","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.tranon.2020.100868_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2018.06.001","article-title":"Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas","volume":"122","author":"Li","year":"2018","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"8","key":"10.1016\/j.tranon.2020.100868_bb0180","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer discovery"},{"issue":"8","key":"10.1016\/j.tranon.2020.100868_bb0185","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2017.04.031","article-title":"MET exon 14 skipping mutations in lung adenocarcinoma: clinicopathologic implications and prognostic values","volume":"12","author":"Lee","year":"2017","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2020.100868_bb0190","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtho.2016.05.016","article-title":"The unique characteristics of MET exon 14 mutation in Chinese patients with NSCLC","volume":"11","author":"Liu","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2020.100868_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.lungcan.2015.10.022","article-title":"MET amplification, protein expression, and mutations in pulmonary adenocarcinoma","volume":"90","author":"Park","year":"2015","journal-title":"Lung cancer (Amsterdam, Netherlands)"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320303600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:38:57Z","timestamp":1761835137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320303600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1936523320303600"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100868","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100868"}}